DiscGenics Competitors

At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.

Acelity is a global advanced wound care company, offering innovative solutions from the hospital to home that improve the lives of patients in more than 90 countries. Our mission is to change the practice of medicine with solutions that speed healing, create economic value and improve patients’ lives. Our shared values drive our company’s personality, culture and priorities by providing a framework for making decision: Customer First, Integrity, A Will to Win, One Acelity. We are the undisputed leader in negative pressure wound therapy and the market leader in collagen dressings. Acelity is headquartered in San Antonio, Texas, with nearly 5,000 employees around the globe. This channel and specific content are intended for a global audience. Patients should consult with their healthcare providers regarding their specific medical conditions, treatments, information on this channel, and risks and benefits of Acelity products. This channel is not a substitute for professional medical advice, diagnosis, or treatment. Not all Acelity products are available in all countries. Acelity is not responsible for, and does not control/endorse materials such as linked 3rd party videos, sites or ads, and makes no representations regarding their accuracy.

Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.